Riskpilot← Back to searchSign inGet full accessQUALIMEDICS A/S
A/SBankruptCVR 16630977Bistrup Hegnsvej 7BGeneral medical practice activities · NACE 8621Est. 19925 employees
Revenue 2023
DKK 2,9M
-33% vs 2022
EBITDA margin
-7.7%
-347% vs 2022
Equity ratio
-96.5%
Financial strength
Net profit 2023
DKK -1,3M
-867% vs 2022
| Revenue | DKK 2,9M | -33% |
| EBITDA | DKK -219K | -347% |
| Net profit | DKK -1,3M | -867% |
| Total assets | DKK 2,3M | -17% |
| Equity | DKK -2,3M | -131% |
| Employees | 5 | — |
Legal name
QUALIMEDICS A/S
CVR number
16630977
Legal form
Aktieselskab
NACE code
8621 · General medical practice activities
Founded
23. december 1992
Share capital
DKK 500.000
Employees
5 (FTE)
VAT registered
No
Audit selected
No
Last report
2023-09-30
Financial year
January – December
Signatory rights
Selskabet tegnes af direktøren eller af et bestyrelsesmedlem eller af bestyrelsesformanden i forening med et bestyrelsesmedlem eller direktøren.
Address
Bistrup Hegnsvej 7B
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.075 | 4.533 | 5.128 | 5.750 | 7.249 | 6.268 | 4.960 | 4.644 | 2.114 | 3.295 | 4.275 | 2.860 |
| Staff expenses | -3.809 | -4.148 | -4.436 | -5.482 | -6.731 | -6.067 | -4.330 | -3.893 | -3.875 | -2.890 | -4.186 | -3.079 |
| EBITDA | 266 | 385 | 692 | 268 | 517 | 201 | 630 | 751 | -1.761 | 405 | 89 | -219 |
| Depreciation & amort. | 25 | -31 | 37 | -32 | -18 | -7 | -25 | -32 | -110 | -187 | -178 | -482 |
| EBIT | 241 | 355 | 655 | 236 | 499 | 194 | 605 | 719 | -1.871 | 218 | -90 | -701 |
| Net financials | 6 | 6 | -2 | 4 | 0 | 7 | 27 | 26 | -33 | -151 | -79 | -154 |
| Profit before tax | 246 | 361 | 653 | 241 | 500 | 201 | 632 | 745 | -1.904 | 67 | -168 | -855 |
| Tax | 62 | 91 | 161 | 53 | 111 | 46 | 140 | 164 | -418 | 16 | -36 | 425 |
| Net profit | 185 | 270 | 491 | 188 | 388 | 155 | 492 | 581 | -1.486 | 51 | -132 | -1.280 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1.622 | 1.809 | 2.212 | 1.672 | 2.334 | 1.405 | 1.874 | 2.104 | 2.584 | 2.915 | 2.810 | 2.342 |
| Equity | 773 | 893 | 1.135 | 722 | 911 | 666 | 1.158 | 1.238 | -748 | -697 | -981 | -2.261 |
| Long-term debt | 0 | 0 | 0 | 0 | 112 | 20 | 144 | 167 | 1.076 | 539 | 1.800 | 1.756 |
| Short-term debt | 849 | 916 | 1.077 | 950 | 1.311 | 700 | 557 | 687 | 2.256 | 3.073 | 1.991 | 2.847 |
| Total debt | 849 | 916 | 1.077 | 950 | 1.423 | 721 | 701 | 854 | 3.331 | 3.612 | 3.791 | 4.602 |
EBITDA margin
-7.7%
This company
15.8%
Market median
-149% vs market
20122023
Equity ratio
-96.5%
This company
38.2%
Market median
-353% vs market
20122023
Return on equity
-127995100.0%
This company
18.4%
Market median
-695625643% vs market
20122023
Net profit margin
-44.8%
This company
8.1%
Market median
-653% vs market
20122023
Asset turnover
1.22×
This company
1.12×
Market median
+9% vs market
20122023
Debt / equity
2.04×
This company
0.62×
Market median
-229% vs market
20122023
- Annual report 2023Filed via CVR / Virk · Period 2022-10-01 – 2023-09-30
- Annual report 2022Filed via CVR / Virk · Period 2021-10-01 – 2022-09-30
- Annual report 2021Filed via CVR / Virk · Period 2020-10-01 – 2021-09-30
- Annual report 2020Filed via CVR / Virk · Period 2019-10-01 – 2020-09-30
- Annual report 2019Filed via CVR / Virk · Period 2018-10-01 – 2019-09-30
- Annual report 2018Filed via CVR / Virk · Period 2017-10-01 – 2018-09-30
- Annual report 2017Filed via CVR / Virk · Period 2016-10-01 – 2017-09-30
- Annual report 2016Filed via CVR / Virk · Period 2015-10-01 – 2016-09-30
- Annual report 2015Filed via CVR / Virk · Period 2014-10-01 – 2015-09-30
- Annual report 2014Filed via CVR / Virk · Period 2013-10-01 – 2014-09-30
- Annual report 2013Filed via CVR / Virk · Period 2012-10-01 – 2013-09-30
- Annual report 2012Filed via CVR / Virk · Period 2011-10-01 – 2012-09-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
KF Management | Management | 2015 | — | — |
CH Management | Management | 1992 | — | — |
JK Audit | Audit | 1992 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 1992 | — | — | |
| Board of Directors | 1992 | — | — | |
| Chairman | 2015 | — | — | |
| Board of Directors | 2011 | — | — | |
| Board of Directors | 2015 | — | — | |
| Board of Directors | 2020 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
KATALYST HOLDING ApS | Company | 100.0% | 100.0% | 2015 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of QUALIMEDICS A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Katrine Flindt | Management | 0 companies |
| Claus Hancke | Management | 0 companies |
| Jens Koch-Nielsen | Audit | 0 companies |
| Marianne Vibeke Obelitz Hancke | Board of Directors | 0 companies |
| Per Harder | Board of Directors | 0 companies |
| Thomas Bøgelund Norvold | Chairman | 0 companies |
| Jesper Hancke | Board of Directors | 0 companies |
| Tom Allan Jensen Kirkebæk | Board of Directors | 0 companies |
| Poul Lentz Flindt | Board of Directors | 0 companies |